Motivation: Combination drug therapies are effective treatments for cancer. However, the genetic heterogeneity of the patients and exponentially large space of drug pairings pose significant challenges for finding the right combination for a specific patient. Current in silico prediction methods can be instrumental in reducing the vast number of candidate drug combinations. However, existing powerful methods are trained with cancer cell line gene expression data, which limits their applicability in clinical settings. While synergy measurements on cell line models are available at large scale, patient-derived samples are too few to train a complex model. On the other hand, patient-specific single-drug response data are relatively more available.
Results: In this work, we propose a deep learning framework, Personalized Deep Synergy Predictor (PDSP), that enables us to use the patient-specific single drug response data for customizing patient drug synergy predictions. PDSP is first trained to learn synergy scores of drug pairs and their single drug responses for a given cell line using drug structures and large scale cell line gene expression data. Then, the model is fine-tuned for patients with their patient gene expression data and associated single drug response measured on the patient ex vivo samples. In this study, we evaluate PDSP on data from three leukemia patients and observe that it improves the prediction accuracy by 27% compared to models trained on cancer cell line data.
Availability And Implementation: PDSP is available at https://github.com/hikuru/PDSP.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215552 | PMC |
http://dx.doi.org/10.1093/bioinformatics/btae134 | DOI Listing |
Sci Total Environ
January 2025
National Engineering Research Center for Efficient Utilization of Soil and Fertilizer Resources, Key Laboratory of Agricultural Environment in Universities of Shandong, College of Resources and Environment, Shandong Agricultural University, Tai'an 271018, China. Electronic address:
Perfluorooctane sulfonate (PFOS) and its new substitute, perfluorobutane sulfonate (PFBS), are increasing in concentration in the environment annually, and their toxicity cannot be ignored. With an increasing amount of PFOS and PFBS entering the environment, especially into farmland soil, it is very likely to pollute tobacco-planting soil. Therefore, we chose tobacco (Nicotiana tabacum L.
View Article and Find Full Text PDFLung Cancer
January 2025
Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
Objectives: The lack of definitive biomarkers presents a significant challenge for chemo-immunotherapy in extensive-stage small-cell lung cancer (ES-SCLC). We aimed to identify key genes associated with chemo-immunotherapy efficacy in ES-SCLC through comprehensive gene expression analysis using machine learning (ML).
Methods: A prospective multicenter cohort of patients with ES-SCLC who received first-line chemo-immunotherapy was analyzed.
Plast Reconstr Surg
December 2024
Copenhagen University Hospital, Department of Plastic Surgery and Burns Treatment, Rigshospitalet, Copenhagen, Denmark.
Background: Capsular contracture is a frequent and severe complication following breast implant surgery. Although several theories on the pathophysiology exist, the exact molecular mechanisms remain unclear. This study aimed to identify the specific genes, signaling pathways, and immune cells associated with capsular contracture.
View Article and Find Full Text PDFJ Immunother
October 2024
Department of Radiation Oncology, Huai'an Hospital Affiliated to Xuzhou Medical University, Huai'an, China.
Colorectal cancer (CRC) ranks third globally in cancer incidence and mortality, posing a significant human concern. Recent advancements in immunotherapy are noteworthy. This study explores immune modulation for CRC treatment.
View Article and Find Full Text PDFIndian J Pathol Microbiol
October 2024
Department of Pathology, Sichuan Taikang Hospital, Chengdu, China.
Objective: To explore more and better liquid biopsy markers of exosomal microRNAs (exo-miRNAs) in renal interstitial fibrosis (RIF) and to preliminary investigate the biological functions and signaling pathways involved in these markers.
Materials And Methods: High-throughput miRNA sequencing was performed on blood and urine exo-miRNAs from three RIF patients and three healthy volunteers, and differential expression analysis and bioinformatic processing were performed.
Results: There were 13 differentially expressed exo-miRNA (DEexo-miRNA) between RIF and healthy blood, and 20 DEexo-miRNAs in urine.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!